LSL Pharma Group Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY
Period Ending	Mar '26 Mar 19, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jul '21 Jul 31, 2021
Market Cap	48	47	40	-	-
Market Cap Growth	16.75%	18.48%	-	-	-
Enterprise Value	69.49	66.81	50.91	0	0
Last Close Price	0.40	0.41	0.49	-	-
PE Ratio	17.41	13.67	-4.41	-	-
PS Ratio	1.79	2.67	3.99	-	-
PB Ratio	1.89	1.90	4.62	-	-
P/TBV Ratio	-	1.74	4.51	-	-
P/FCF Ratio	-	-9.92	-5.17	-	-
P/OCF Ratio	-	-28.67	-5.65	-	-
EV/Sales Ratio	2.59	3.76	5.08	-	-
EV/EBITDA Ratio	17.32	28.64	-58.52	-	-
EV/EBIT Ratio	49.11	81.08	-25.47	-	-
EV/FCF Ratio	-	-14.00	-6.59	-	-
Debt / Equity Ratio	1.08	0.79	1.26	2.68	-0.59
Debt / EBITDA Ratio	7.55	9.27	-18.70	-1.23	-1.83
Debt / FCF Ratio	-8.13	-4.53	-2.11	-3.82	-
Net Debt / Equity Ratio	1.12	0.86	1.88	3.00	-0.59
Net Debt / EBITDA Ratio	7.43	9.15	-18.69	-1.23	-1.83
Net Debt / FCF Ratio	-8.00	-4.47	-2.10	-3.82	-
Asset Turnover	0.47	0.42	0.34	0.60	0
Inventory Turnover	1.67	1.86	2.37	7.02	-
Quick Ratio	0.47	0.54	0.18	0.11	0.09
Current Ratio	1.53	1.59	0.48	0.38	0.09
Return on Equity (ROE)	11.85%	19.78%	-121.50%	-315.83%	1700.80%
Return on Assets (ROA)	2.76%	1.92%	-6.87%	-102.01%	-346.35%
Return on Invested Capital (ROIC)	3.03%	2.23%	-8.67%	-132.06%	78.60%
Return on Capital Employed (ROCE)	3.47%	2.76%	-12.68%	-179.76%	32.28%
Earnings Yield	5.80%	7.32%	-22.68%	-	-
FCF Yield	-	-10.08%	-19.32%	-	-
Buyback Yield / Dilution	-5.90%	-17.37%	-23.67%	-	-

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.